Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS

Trial Profile

Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Sodium phenylbutyrate/tauroursodeoxycholic acid (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CENTAUR
  • Sponsors Amylyx Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to an Amylyx Pharmaceuticals media release, company is planning an open label extension of this study.
    • 08 Aug 2017 According to an Amylyx Pharmaceuticals media release, first patient has been dosed.
    • 09 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top